Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, today announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma www.resolvetherapeutics.com. A significant number of trauma patients admitted to the hospital each year suffer from polytrauma, with multiple, life-threatening injuries requiring immediate surgical intervention. Many of these patients experience po...
Today, Sephora proudly unveils its “We Belong To Something Beautiful” signature campaign with Haus Labs By Lady Gaga in partnership with Born This Way Foundation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528841282/en/ A Shared Vision: Lady Gaga and Sephora Champion Beauty and Belonging At the heart of this campaign is a new film featuring Lady Gaga sharing her vision of beauty as being part of a kind, inclusive, joyful, i...
AVEDA, a purpose-driven pioneer of plant-powered, high-performance beauty announces its debut in the U.S. Amazon Premium Beauty store, bringing its assortment of vegan hair, skin, body and lifestyle products to new consumers across the country. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528898881/en/ “With the launch of AVEDA in the U.S. Amazon Premium Beauty store, we’re not only introducing more people to the world of AVEDA...
BELFOR, the world’s leading provider of disaster recovery and property restoration services, recently participated in the Asia Claims Convention 2025, held from 13 to 15 May 2025 in Osaka, Japan. The event brought together 231 attendees representing 103 companies from across the insurance, risk management and restoration industries. At the heart of BELFOR’s contribution was a compelling presentation by Mr. Guido Gavio, Asia Complex Loss Director, titled “How Digital Transformation Is Reshapin...
Storm Reply, the Reply Group company specialising in innovative cloud-based solutions and services, is supporting Audi’s Cloud Foundation Services team in enhancing its cloud management activities through the introduction of Devbot, a digital assistant powered by Agentic AI technologies. Designed to optimise the use of cloud infrastructure, Devbot automates the handling of recurring support requests. Preparing to deploy a system where Audi employees receive personalized recommendations in real ...
THIS INFORMATION RELATES TO AN OFFERING OF SECURITIES OFFERED AND SOLD PURSUANT TO RULE 144A AND/OR REGULATION S (EXEMPTIONS FROM THE U.S. REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND IS ONLY DIRECTED AT QUALIFIED INSTITUTIONAL BUYERS UNDER RULE 144A OR OUTSIDE THE UNITED STATES OF AMERICA UNDER REGULATION S TO WHOM THE DISTRIBUTION OF THIS INFORMATION, WHETHER DIRECTLY OR INDIRECTLY, IS NOT OTHERWISE UNLAWFUL Mehiläinen Yhtiöt Oy Announces Pr...
Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 and March 2024, respectively2. ...
Westlake Corporation (NYSE: WLK) announced today that Westlake Epoxy will collaborate with Alpha Recyclage Composites to support them in scaling up the recycling capacity for carbon fiber composite materials. This collaboration will provide support to Westlake’s composite customers in their development of improved circular options for both production (scrap or off spec composite materials that otherwise become waste) and end-of-life waste. The recovery of the carbon fibers from composite materi...
Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: “Breath of change: redefining respiratory allergy care with remission in sight”: with environmental ...
Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic (IVD) test for the assessment of amyloid pathology in patients being evaluated for Alzheimer’s disease and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA cleared blood-based IVD test in the U.S. to aid to identify patients with am...